Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer.

Weisong LiKai ZhangWenjun WangYuanyuan LiuJianming HuangMeihong ZhengLing LiXinyu ZhangMinjuan XuGuofang ChenLiefeng WangShuyong Zhang

Published in: Journal of experimental & clinical cancer research : CR (2024)

These findings provide a preclinical framework supporting the potential of dual targeting HER2 and VEGFR as a promising therapeutic strategy to improve outcomes in patients with OC.

Keyphrases

vascular endothelial growth factor
cancer therapy
human health
stem cells
risk assessment
endothelial cells
mesenchymal stem cells